Core Insights - The Beijing-Tianjin-Hebei Free Trade Zone focuses on key sectors such as biomedicine, digital economy, and modern logistics, creating a comprehensive opportunity list for 41 key enterprises to enhance supply chain capabilities and regional collaboration [1][2] Group 1: Biomedicine Industry - The opportunity list integrates information from various segments of the biomedicine supply chain, including drug research and development, production, distribution, and clinical applications, highlighting collaboration opportunities in AI drug development, gene editing, clinical trials, and customs services [1] Group 2: Digital Economy Industry - The opportunity list consolidates data from multiple aspects of the digital economy supply chain, such as computing power, data, security, and application scenarios, revealing collaboration opportunities in resource sharing, cross-border data flow, cybersecurity, and industrial digital empowerment [1] Group 3: Modern Logistics Industry - The opportunity list encompasses information from international logistics, transportation services, supply chain finance, and cold chain storage, showcasing collaboration opportunities in multimodal transport, cold chain logistics, bonded warehousing, and the establishment of logistics information platforms [1] Group 4: Overall Development Strategy - The initiative aims to promote innovative development across the entire industry chain, fostering a cross-regional and cross-industry innovation ecosystem, enhancing traditional industries, and supporting the growth of emerging sectors to accelerate high-quality regional economic development [2] Group 5: Future Directions - The Free Trade Zone will continue to build platforms for communication and collaboration based on actual enterprise needs, aiming to align supply and demand effectively while leveraging the technological innovation strengths of Beijing, advanced manufacturing capabilities of Tianjin, and geographical advantages of Hebei [2]

Group 1 - The company, Nanmo Biology (688265.SH), reported a revenue of approximately 421.26 million yuan for the fiscal year 2025, representing a year-on-year growth of 10.50% [1] - The net profit attributable to the parent company was approximately 32.43 million yuan, showing a significant year-on-year increase of 399.29% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately 9.41 million yuan, marking a turnaround from loss to profit compared to the same period last year [1] Group 2 - The domestic biopharmaceutical industry showed signs of recovery during the reporting period, contributing to an increase in the company's industrial revenue compared to the previous year [1] - The company has implemented measures such as adjusting cage layouts, controlling procurement prices, and optimizing business processes to strengthen cost control and improve operational efficiency, leading to a reduction in costs [1] - There was an increase in non-recurring gains, such as government subsidies, compared to the previous year [1]

另据浦东新区官方表示，2026年全年，浦东新区共计划实施380项重大工程，预计总投资约1.52万亿 元，年度投资额将达到1745亿元。 浦东坚持以科技创新引领，推动科技创新和产业创新深度融合，加快建设现代化产业体系，一批涉及十 大特色产业集群的科技创新项目加快建设。此次开工的扬子江药业集团上海生命科学产业园改扩建、东 方基因全球数字化研发创新总部等10项科技产业项目，涉及人工智能、生物医药等浦东重点发展的先导 产业和重要领域。 此次开工的9项市政交通工程包括：为机场四期和东方枢纽配套的川南奉公路提升改建工程、南横二路 新建工程，形成上海中心城区"井字形"骨架性主干路网的南北通道浦东段一期重要节点工程等。 浦东新区官方表示，到2030年，浦东将全面建成"立体互联、枢纽引领、多元融合、管理创新、智慧绿 色"综合交通体系，实现"10、15、30"交通出行——中心城区超80%居民10分钟内步行或骑行可达轨交 站点、全域机动车15分钟进入高快速路系统、街镇中心及特色产业园区30分钟直达主要交通枢纽。 随着上述重大工程项目陆续启动建设，浦东新区官方表示，浦东今年计划实施的380项重大工程中，工 程在建和新开项目数比例已达 ...

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating a robust business strategy focused on international expansion and innovation [1] Financial Performance - The company achieved total operating revenue of 2.868 billion yuan, representing a year-on-year increase of 26.35% [1] - The net profit attributable to shareholders reached 248 million yuan, up 22.91% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 252 million yuan, reflecting a substantial year-on-year growth of 40.82% [1] Business Strategy - The company strengthened its brand and overseas business team, actively developing international partnerships and expanding into overseas markets [1] - Emphasis was placed on innovation and quality management, leading to strong growth in the life science reagent business, which saw an increased revenue share compared to 2024 [1] - The high gross margin of the life science reagent business is attributed to its focus on cutting-edge scientific research and new drug development, providing diverse product and technical support to clients in the early stages of drug discovery [1]

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating a robust business strategy focused on international expansion and innovation [1] Financial Performance - The company achieved total operating revenue of 2.868 billion yuan, representing a year-on-year increase of 26.35% [1] - The net profit attributable to the parent company was 248 million yuan, up 22.91% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses reached 252 million yuan, reflecting a substantial year-on-year growth of 40.82% [1] Business Strategy - The company strengthened its brand and overseas business team, actively developing international partnerships and expanding into overseas markets [1] - Emphasis was placed on innovation-driven strategies and quality management, leading to strong growth in the life sciences reagent business [1] - The revenue share from the life sciences reagent business increased significantly compared to 2024, with a focus on cutting-edge scientific research and new drug development [1]

Group 1 - The stock price of Zhendong Pharmaceutical has shown volatility in the past week, closing at 6.16 yuan on February 27, 2026, with a daily increase of 0.65% and a cumulative increase of 0.49% over the last five days [1] - On February 26, 2026, the stock price experienced a notable decline of 1.77%, with a net outflow of 16.08 million yuan from major funds and a turnover rate of 2.54% [1] - Technical analysis indicates that the current stock price is near the middle track of the 20-day Bollinger Bands, with a resistance level at 6.55 yuan and a support level at 5.55 yuan [1] Group 2 - On February 24, 2026, Zhendong Pharmaceutical announced the resignation of its president Yang Lianmin due to retirement, with Lei Zhenhong elected as the employee representative director [2] - The company also announced an investment of 30 million yuan from its own funds to participate in a biopharmaceutical fund, holding a 28.57% stake [2] - The 2024 annual board work report mentioned the completion of efficacy evaluation for a new skin drug in the innovative drug sector and progress on the FDA registration of a compound injection [2] Group 3 - The Q3 2025 financial report indicated that Zhendong Pharmaceutical's revenue for the first three quarters was 2.215 billion yuan, a year-on-year decrease of 2.42%, while the net profit attributable to shareholders was 20.3641 million yuan, down 49.25% year-on-year [3] - In Q3 alone, the revenue was 758 million yuan, with a net profit of 12.4328 million yuan, reflecting a year-on-year increase of 31.34%, and a turnaround in non-recurring net profit [3] - The decline in performance was primarily attributed to reduced investment income and increased income tax expenses [3] Group 4 - Institutional research indicates that the market attention towards Zhendong Pharmaceutical is average, with the latest sentiment being neutral; 0% of institutional ratings are positive, 0% are negative, and 100% are neutral [4] - Earnings forecasts suggest that the earnings per share for 2024 will be negative, and the proportion of fund holdings is relatively low [4]

Core Viewpoint The Shanghai Municipal Market Supervision Administration has issued the "2026 Annual Application Guidelines for Special Funds for Standardization Promotion Projects" to enhance the implementation of the city's standardization strategy and encourage local entities to actively participate in standardization work [1][31]. Group 1: Application Subjects - Any legally registered entity in Shanghai can apply for standardization promotion projects as the main responsible unit, provided the project has not received other municipal financial support [2][32]. - Multiple entities involved in the same project will generally have support granted only to the entity with the highest participation [2][32]. - A single entity can apply for no more than 5 projects in the same category and a total of no more than 10 projects in a given application year [2][32]. Group 2: Application Scope and Conditions A. Standard Formulation and Revision Projects - Projects related to international standards, foreign advanced standards, national standards, industry standards, and local standards in Shanghai, with implementation dates between January 1, 2025, and September 30, 2025, are eligible [3][33]. - Group standards recognized by the government during the same period are also included [3][33]. B. Standardization Technical Organization Projects - Projects that involve leading or significantly participating in the formulation of international standards, national standards, and local standards are eligible [4][35]. - Projects that undertake international and national standardization technical organization roles in 2025 are also included [36][38]. C. Standardization Demonstration Pilot Projects - National and Shanghai municipal standardization pilot projects approved for implementation in 2025 that achieve significant results upon acceptance are eligible [39][40]. D. Standardization Activity Projects - Major standardization activities held in Shanghai by entities outside the municipal standardization technical organization in 2025 are eligible [41]. Group 3: Key Supported Areas - The special funds will focus on high-tech fields such as integrated circuits, biomedicine, artificial intelligence, and new energy vehicles, among others [14][42]. - Modern service industries including digital economy, financial technology, and cultural tourism are also prioritized [15][42]. - Areas related to social management, public services, agriculture, and environmental protection are included as well [16][17][44]. Group 4: Automatic Eligibility - Projects that meet specific criteria, such as leading the formulation of international standards listed in the national standard committee's 2025 ISO/IEC standard revision list, will be automatically selected without the need for application [45][46]. Group 5: Application Process - Entities must register on the "One Network for All" portal by March 20, 2026, to apply for funding [47][50]. - The application process includes selecting the appropriate project category and completing the online submission [52][55].

Group 1 - The core viewpoint of the article is that Nanmo Biological announced its financial projections for 2025, indicating significant growth in both revenue and net profit [1] Group 2 - The total operating revenue for 2025 is projected to be 421.2586 million yuan, representing a year-on-year increase of 10.50% [1] - The net profit attributable to the parent company is expected to reach 32.4313 million yuan, showing a remarkable year-on-year growth of 399.29% [1]

Group 1 - The core viewpoint of the article highlights the significant growth in the performance of Aopumai, with a reported revenue of approximately 355 million yuan for the fiscal year 2025, representing a year-on-year increase of 19.4% [1] - The net profit attributable to shareholders of the listed company is approximately 41.7 million yuan, showing a substantial year-on-year increase of 98.07% [1] - Basic earnings per share reached 0.37 yuan, which is a 94.74% increase compared to the previous year [1] Group 2 - In February, China's AI usage surpassed that of the United States for the first time, indicating a significant shift in the global AI landscape [1] - Four major AI models from China ranked among the top five globally, reflecting the rapid growth in domestic computing power demand [1]

Market Performance - The Hong Kong stock market showed an upward trend on February 27, with the Hang Seng Index rising by 0.95% to close at 26,630.54 points, the Hang Seng Tech Index increasing by 0.56% to 5,137.84 points, the National Enterprises Index up by 0.51% to 8,859.49 points, and the Red Chip Index gaining 0.63% to 4,439.65 points [1] Sector Performance - Strong performance was observed in sectors such as optical communication, steel, non-ferrous metals, rare earths, and innovative pharmaceuticals. Notable individual stock performances included Longi Green Energy rising nearly 10%, CanSino Biologics up by 7%, and China Shenhua Energy increasing by nearly 6% [1] - The steel sector was particularly active, with Asia Pacific Resources rising nearly 12% and Angang Steel up over 5% [1] - The biopharmaceutical sector also showed strength, with WuXi AppTec rising over 3% [1] Company Earnings - Baidu Group reported total revenue of 129.1 billion yuan for 2025, with AI business revenue reaching 40 billion yuan and a fourth-quarter revenue of 32.7 billion yuan, reflecting a 5% quarter-on-quarter growth [2] - BeiGene achieved its first annual profit with total revenue of 38.205 billion yuan, marking a 40.4% year-on-year increase [2] - CanSino Biologics reported total revenue of 1.068 billion yuan for 2025, a 26.18% year-on-year growth, and a net profit of 27.8727 million yuan, indicating a return to profitability [2] - Sun Hung Kai Properties announced a mid-year revenue of 52.705 billion HKD for the six months ending December 31, 2025, a 31.98% year-on-year increase, and a profit of 10.247 billion HKD, up 36.21% [2] Analyst Insights - According to a report from China Merchants Securities, the current valuation of the Hong Kong tech sector has dropped to historical lows. The Hang Seng Tech Index compared to the A-share ChiNext Index indicates that the tech sector is significantly undervalued. The report suggests a high probability of success in investing in Hong Kong tech stocks in the context of AI development and national technological advancement [2]